Maryvonne HIANCE

Vice Chairman, Ose Immunotherapeutics and President of France biotech.
Maryvonne Hiance specializes in nuclear science and served, for 14 years, as manager of neutron studies at Framatome (Areva). Over a 20-year period, she held the position of General Manager at innovative biotechnology companies including SangStat Atlantic, DrugAbuse Sciences and TcLand. She also founded and served as General Manager of Strategic Ventures, a consulting company providing support to technological companies.
Maryvonne Hiance has been a member of the French Strategic Council for Innovation and has served as Advisor to the French SMEs and Industry Ministry.
In 2008, she co-founded and served as Chairman of the Board of Effimune, a biotechnology company specialized in immune regulation with clinical applications in autoimmunity, transplantation and immune-oncology.
Vice Chairman of the Board of OSE Immunotherapeutics, Maryvonne Hiance also serves as Strategy Advisor to the company’s Management. On 30th June 2016, she was elected Chairman of France Biotech, the association of Biotechnology and Life Sciences companies.
Maryvonne Hiance holds an Engineering Degree from the « Ecole Polytechnique Feminine », Paris, and a Nuclear Engineering Degree from the « Institut des Sciences et Techniques », Grenoble.